John Parker, Pediatric Health Innovation Expert, Joins as Strategic Advisor

Intervale, New Hampshire February 1, 2024: Cytokind, Inc, a hybrid medtech/drug discovery company using the power of light to treat the Silent Symptoms of multiple sclerosis, is pleased to announce the appointment of John Parker to its Strategic Advisory Board. With a wealth of experience in the healthcare innovation sector, John Parker’s addition strengthens Cytokind’s mission to dramatically improve the quality of life of MS patients.

John Parker, Founder and Managing Director of Springhood Ventures, a firm focusing on child health innovation, brings a unique perspective to the board. He also manages the program-related investment initiative at the Charles H. Hood Foundation. With 25 years of experience in venture capital, private equity, and hedge funds, John’s financial expertise and strategic insights are expected to play a crucial role in accelerating the development and adoption of Cytokind’s innovative light-based therapies for multiple sclerosis.

John MacMahon, CEO of Cytokind, Inc., commented, “We are thrilled to welcome John Parker to our Strategic Advisory Board. His extensive background in funding child health solutions aligns perfectly with Cytokind’s commitment to improving the lives of those affected by multiple sclerosis and other autoimmune diseases. John’s expertise will be invaluable as we continue to advance our phototherapy approach.”

“I am excited to collaborate with Cytokind and contribute to their groundbreaking work for both pediatric and adult MS patients. The potential of harnessing light to address the silent symptoms of this disease is truly remarkable,” said Parker. “The parents of pediatric patients know their children are often ignored by companies. Cytokind’s approach moves them to the forefront. I look forward to helping make that happen for pediatric MS.”

About Cytokind: Cytokind, Inc. is a hybrid medical device/drug discovery company advancing a translational application of phototherapy from dermatology to neurology. With a focus on harnessing the power of light and innovative therapies, Cytokind, Inc. is dedicated to strengthening the human immune system and revolutionizing treatment approaches for individuals living with MS.


For more information, contact:

John MacMahon

603 264 7751